Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors

October 19, 2010 By Bio-Medicine.Org

SEOUL, South Korea, Oct. 19 /PRNewswire/ — BioMolecular
Therapeutics, Inc. (BMT, Inc.), a new Seoul-based RNAi therapeutics
company with a proprietary technology designed to reduce
significantly deleterious side effects triggered by conventional
siRNA, announced that it has launched its global operations. The
company is currently developing a novel RNAi therapeutic for
age-related macular degeneration (AMD), based on its asymmetric
shorter-duplex siRNA (asiRNA) technology, originally published in
Molecular Therapy in 2009 as a featured article. Early
studies suggest that the asiRNA technology will allow the
application of RNAi therapeutics in fields where innate immune
stimulation needs to be avoided, such as AMD. The goal of an RNAi
therapeutic is to target specifically only the gene or genes
implicated in the disease. In AMD, activation of the innate immune
response could elicit off-target effects, potentially hastening the
progression of the disease. Two previous clinical trials using
traditional siRNA as an AMD therapeutic were terminated at Phase II
and III because of unintended activation of the patients’ immune
response.

BMT’s leadership team includes Dong-ki Lee, Ph.D., the inventor
of the company’s proprietary technology, and Sun woo Hong, Ph.D.,
BMT’s founding CEO. Dr. Dong-ki Lee is associate professor of
chemistry at Sungkyunkwan University in Suwon, Korea, and the
recipient of the prestigious Global Research Laboratory grant from
the Korean government for the development of novel RNAi
therapeutics. Dr. Sun Woo Hong has strong expertise in siRNA and
genomics research, and was research professor at Dongguk University
in Seoul, Korea. The company has also named two key advisors,
Jayakrishna Ambati, M.D., ophthalmologist and professor at
University of Kentucky Medical School, and Johannes Fruehauf, M.D.,
Ph.D., an experienced biotechnology executive and a specialist in
RNAi therapeutics.  

Dr. Ambati will serve as head of BMT’s

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech